Noviello, Teresa Maria Rosaria http://orcid.org/0000-0002-3411-6752
Di Giacomo, Anna Maria
Caruso, Francesca Pia http://orcid.org/0000-0002-2206-1459
Covre, Alessia
Mortarini, Roberta
Scala, Giovanni
Costa, Maria Claudia http://orcid.org/0000-0001-7429-7220
Coral, Sandra
Fridman, Wolf H. http://orcid.org/0000-0002-1332-0973
Sautès-Fridman, Catherine http://orcid.org/0000-0003-1735-8722
Brich, Silvia
Pruneri, Giancarlo
Simonetti, Elena
Lofiego, Maria Fortunata
Tufano, Rossella
Bedognetti, Davide http://orcid.org/0000-0002-5857-773X
Anichini, Andrea http://orcid.org/0000-0001-5096-5538
Maio, Michele http://orcid.org/0000-0002-0323-6321
Ceccarelli, Michele
Article History
Received: 22 December 2022
Accepted: 18 August 2023
First Online: 22 September 2023
Competing interests
: A.M.D.G. has served as consultant and/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol-Myers Squibb, Merck Sharp Dohme, Pierre Fabre, and Sanofi. W.H.F. has served as consultant and/or advisor to AstraZeneca, Adaptimmune, Catalym, OOSE Immunotherapeutics, and Novartis, and reports receiving speakers bureau honoraria from Bristol-Myers Squibb. MM has served as consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and own shares in Theravance and Epigen Therapeutics, Srl. MC serves as consultant and/or advisor to Moderna Therapeutics and is the founder and owns shares of Immunomica srl. Other authors have nothing to declare.